EU Launches Antitrust Probe Over Lundbeck Drug

Law360, New York (January 7, 2010, 2:01 PM EST) -- The European Commission has opened a formal antitrust investigation into Danish drugmaker H. Lundbeck A/S, principally examining whether the company has restricted the entry of a generic version of its antidepressant drug citalopram.

The EC said Thursday that it intends to probe whether agreements the company made have blocked generic rivals from producing their own versions of citalopram. The Commission said the formal investigation of Lundbeck was prompted by knowledge acquired during the regulator's recent inquiry into the pharmaceutical sector, particularly related to ways branded drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.